InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
61,095.34
(
0.49%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Telephonics

Send PM Follow Ignore
Followers 3
Posts 1277
Boards Moderated 1
Alias Born 04/02/2003

Telephonics

Re: jbog post# 3085

Wednesday, 01/10/2007 11:00:34 AM

Wednesday, January 10, 2007 11:00:34 AM

Post# of 4764
Merck News Release

Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III
Metastatic Colorectal Cancer Study


Darmstadt, Germany, January 10, 2007 – Merck KGaA announced today that a
Phase III study of Erbitux® (cetuximab) plus irinotecan-based therapy met
the primary endpoint of increasing median duration of progression-free
survival in patients with previously untreated metastatic colorectal cancer
(mCRC). This randomized Phase III international trial, known as CRYSTAL
Cetuximab combined with iRinotecan in first line therapY for metaSTatic
colorectAL cancer, studied patients treated with Erbitux plus FOLFIRI
(irinotecan-based chemotherapy) compared with FOLFIRI alone.

The complete news release can be downloaded at the following link:
http://me.merck.de/n/5BE1C55BDCA32E01C125725E004DFBE1/$FILE/crystal_e.pdf

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up